NCT06083857 2026-03-11PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung CancerM.D. Anderson Cancer CenterPhase 1/2 Active not recruiting3 enrolled
NCT04739358 2023-10-18CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLCCriterium, Inc.Phase 1/2 Terminated2 enrolled